"drugs-controller-general-of-india-dcgi"

Cervical cancer is the second most common cause of cancer deaths, after breast cancer, in women of reproductive age. India accounts for about a fifth of the global burden, with 1.23 lakh cases and around 67,000 deaths per year. The disease is largely preventable and a combination of early screening and vaccination can be a […]

Hyderabad: Dr Reddy’s Laboratories said on Tuesday the company will launch its molnupiravir capsules 200mg under its brand name Molflu across India. The drug will be priced at Rs 35 per capsule with 10 capsules contained per strip, and the total course of 40 capsules over five days costing Rs 1,400. Molflu is expected to […]

Bharat Biotech's 'pre-submission' meeting with the World Health Organization (WHO) will take on Wednesday for the approval for Covaxin.

The recommendation comes in light of a report that Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research – uses NBCS during the production stage.

This will be followed by the clinical trial of children in the age-group of 2-6 years.

The court declined to pass any interim order staying the permission, granted on May 12, for clinical trials

"In the trial, the vaccine will be given by intramuscular route in two doses at day 0 and day 28," it said.

Phase-III clinical trials with Pegylated Interferon Alpha 2b, which the company sells under the brand name 'PegiHep' have shown promising results in treating COVID-19, Zydus Cadila said

The company "will be leveraging its manufacturing capabilities for the production of Sputnik V COVID-19 vaccine," Gland Pharma said in a regulatory filing.